NYSE:VAPO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Vapotherm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VAPO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.3%

VAPO

-3.3%

US Medical Equipment

-3.3%

US Market


1 Year Return

165.7%

VAPO

13.7%

US Medical Equipment

10.9%

US Market

Return vs Industry: VAPO exceeded the US Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: VAPO exceeded the US Market which returned 10.9% over the past year.


Shareholder returns

VAPOIndustryMarket
7 Day-10.3%-3.3%-3.3%
30 Day-15.0%-2.5%-5.7%
90 Day-36.8%12.2%8.2%
1 Year165.7%165.7%14.7%13.7%13.4%10.9%
3 Yearn/a69.0%64.7%34.9%25.9%
5 Yearn/a140.9%122.6%84.6%63.8%

Price Volatility Vs. Market

How volatile is Vapotherm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vapotherm undervalued compared to its fair value and its price relative to the market?

4.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VAPO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VAPO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VAPO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: VAPO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VAPO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VAPO is overvalued based on its PB Ratio (4.7x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Vapotherm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VAPO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VAPO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VAPO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VAPO's revenue (0.8% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: VAPO's revenue (0.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VAPO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Vapotherm performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VAPO is currently unprofitable.

Growing Profit Margin: VAPO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.

Accelerating Growth: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: VAPO has a negative Return on Equity (-33.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vapotherm's financial position?


Financial Position Analysis

Short Term Liabilities: VAPO's short term assets ($187.9M) exceed its short term liabilities ($27.3M).

Long Term Liabilities: VAPO's short term assets ($187.9M) exceed its long term liabilities ($42.5M).


Debt to Equity History and Analysis

Debt Level: VAPO's debt to equity ratio (33.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if VAPO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VAPO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VAPO has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 12.1% each year.


Next Steps

Dividend

What is Vapotherm current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VAPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VAPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VAPO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VAPO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VAPO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Joe Army (56 yo)

8.25yrs

Tenure

US$3,004,481

Compensation

Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army served as the Chief Executive Officer and President of Salient ...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD3.00M) is about average for companies of similar size in the US market ($USD3.07M).

Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Army
CEO, President & Director8.25yrsUS$3.00m2.63%
$ 17.1m
John Coolidge
Vice President of Operations6.5yrsUS$816.88k0.33%
$ 2.2m
Gregoire Ramade
Senior VP & Chief Commercial Officerno dataUS$807.85k0.042%
$ 272.5k
William Niland
no datano datano data
John Landry
CFO, Senior VP8.08yrsUS$277.31k0.46%
$ 3.0m
Anthony Haagen
Vice President of Legal & Complianceno datano datano data
Lindsay Becker
Vice President of Human Resources4.25yrsno data0.12%
$ 808.7k

7.3yrs

Average Tenure

50yo

Average Age

Experienced Management: VAPO's management team is seasoned and experienced (7.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Army
CEO, President & Director8.25yrsUS$3.00m2.63%
$ 17.1m
James Liken
Independent Chairman of the Board7.92yrsUS$183.74k0.37%
$ 2.4m
Craig Reynolds
Independent Director10.08yrsUS$153.74k0%
$ 0
Elizabeth Weatherman
Independent Director2.92yrsUS$153.74k0.48%
$ 3.1m
Marina Hahn
Independent Director2.92yrsUS$141.24k0.078%
$ 508.4k
Anthony Arnerich
Independent Director7.5yrsUS$141.24k0.024%
$ 157.3k
Geoffrey Pardo
Independent Director6.58yrsUS$148.74k0%
$ 0
Lance Berry
Independent Director0.67yrno data0.0096%
$ 62.7k

7.0yrs

Average Tenure

61yo

Average Age

Experienced Board: VAPO's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VAPO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.1%.


Top Shareholders

Company Information

Vapotherm, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vapotherm, Inc.
  • Ticker: VAPO
  • Exchange: NYSE
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$650.251m
  • Shares outstanding: 25.57m
  • Website: https://www.vapotherm.com

Number of Employees


Location

  • Vapotherm, Inc.
  • 100 Domain Drive
  • Exeter
  • New Hampshire
  • 3833
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VAPONYSE (New York Stock Exchange)YesCommon StockUSUSDNov 2018
VA21DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2018

Biography

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 06:43
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.